post

Current Clinical Trials

The MU-Veterinary Health Center (VHC) is currently seeking patients for enrollment in funded oncology clinical trials. Study goals and suitability for each patient are discussed in detail with the clients prior to enrollment. Although clinical trial enrollment may not be the best option for all patients, in many cases, clinical trial participation provides the opportunity to receive novel, cutting-edge therapies free of charge or at a reduced cost and may facilitate treatment of pets where it would not otherwise be possible due to financial constraints or lack of other therapy options. Criteria for enrollment are outlined for each tumor type below. Please direct referrals or questions to Debbie Tate, RVT, VTS (clinical trials coordinator) or the Oncology Clinical Trials Service at 573-882-7821.

Learn about opportunities to participate in clinical trials at other institutions at vetcancertrials.org.

Use of CT/18F-FDG PET Imaging in the Prognosis and Pathologic Evaluation of Soft Tissue Sarcomas

The aim of the project is to determine the biologic behavior of sarcomas on PET/CT and correlate it with a more traditional histological grading system. This will be accomplished by using a well-established methodology which utilizes 18F-Fluorodeoxglucose Positron Emission Tomography (18F-FDG-PET). The hypothesis is that 18F-FDG-PET will have variable glycolytic activity depending upon tumor grade and that the initial standardized uptake values (SUV) can be associated with patient prognosis and survival.

Criteria:

  • Histologic confirmed soft tissue sarcoma
  • CBC, Chemistry panel, UA, FNA of draining lymph node, thoracic radiographs, +/- abdominal U/S
  • Adequate renal, hepatic and hematologic parameters.
  • No significant co-morbidities
  • Definitive surgery performed at UMC Veterinary Health Center

Exclusion:

  • Recurrent sarcoma
  • Prior chemotherapy or radiation therapy
  • Tumor < 10 mm

Therapy:

  • CT/18F-FDG-PET scan.
  • Definitive surgery performed at UMC Veterinary Health Center
  • Histopathologic evaluation of tumor.

Benefit:

  • Study to pay $1000.00 towards CT/18F-FDG-PET, plus $500.00 towards surgery. For total of $1500.00

       Contact Faculty Person: Dr. Jeff Bryan, and Dr Emily Miller


CTI-52010

CTI-52010 is a new nanoparticle taxane drug that has been developed to avoid the allergic reactions of earlier taxanes. It has already been shown to be safe in normal dogs. This clinical trial will refine the proper drug dosage for dogs with cancer and determine whether there is evidence of efficacy when administered subcutaneously.

Criteria:

  • Any tumor (except osteosarcoma, lymphoma , prostate carcinoma) confirmed by histopathology or cytology
  • Normal CBC, renal and liver function, UA and thoracic radiographs at first visit.
  • Washout from last chemotherapy- time depends upon drug
  • Patient must weigh over 5 kgs

Therapy:

  • One subcutaneous injection of CTI-52010
  • Jugular catheter placement and pharmacokinetic samples taken at various intervals over 24 hours post injection
  • CBC, chemistry panel, UA on days 0, 7, 14, 21, 28. Thoracic radiographs every 2 months.

Benefit:

  • Once enrolled study is fully funded. Treatment includes: free drug and drug administration, hospitalization for 1st night, blood work, and office calls.
  • Initial staging is owner’s responsibility.

Contact Faculty Person: Dr. Kim Selting


NHA-cisplatin

NHA-cisplatin is a new hyaluronic acid nanoparticle encapsulating cisplatin. This formulation selectively traffics the drug to tumor and draining lymphatic’s after intra- and peri-tumoral injection. In a pilot trial of NHA-cisplatin in soft-tissue sarcoma, the formulation resulted in similarly favorable tumor and plasma distributions and characteristics in dogs as reported in mice. This clinical trial will identify a model of disease that could benefit significantly from advancing this formulation to market. This is a dose escalation study

Criteria:

  • Oral or digital squamous cell carcinomas, mammary carcinomas, any solid malignant tumor accessible for injection confirmed by histopathology or cytology
  • CBC, chemistry panel, UA and thoracic radiographs and/or abdominal U/S at first visit.
  • 21 day washout from last chemotherapy
  • FNA and cytology of draining LN
  • NO NSAIDS during trial or within 7 days of starting trial
  • Normal renal and liver function
  • NO previous immunotherapy or radiation therapy
  • Performance score of 0 or 1
  • Greater than 9 week life expectancy
  • Tumor > 2 cm in longest dimension
  • Patient must weigh over 10 kgs

Therapy:

  • NHA-cisplatin injection every 3 weeks for a total of 4 treatments
  • Maropitant (2mg/kg x 4 days, first dose prior to each NHA-cisplatin injection).
  • CBC, chemistry panel, on days 0, 7, 21, 28, 42, 49, 63, 70. UA on days 0, 21, 42, and 63. Thoracic radiographs and/or abdominal ultrasound on day 0 and 63, then every 3 months thereafter.

Benefit:

  • Once enrolled study is fully funded. Assistance with travel costs will be provided. Treatment includes: free drug and drug administration, hospitalization for 1st night, blood work, imaging (radiographs, CT, U/S) and office calls.
  • Initial office visit and staging are owner’s responsibility. The cost of staging tests of qualified dogs will be covered.

Contact Faculty Person: Dr. Jeff Bryan


Canine Cachexia Study

The true prevalence of cachexia in canine patients has not been determined, due in part to euthanasia when a pet’s quality of life declines and weight loss ensues. The objectives for this study are to determine toxicity, including cardiovascular effects of the final drug candidate of MC4 peptide receptor antagonist and to determine preliminary efficacy of MC4 peptide receptor antagonist in dogs with cachexia.

Criteria:

  • History of 5% or greater with loss within past three months
  • Radiation and chemotherapy allowed at clinician discretion
  • Washout of 2 days required for appetite stimulants.
  • CBC, chemistry panel, UA, and abdominal ultrasound within 14 days of enrollment
  • Corticosteriod use allowed if > 14 days prior to enrollment

Exclusion:

  • Concurrent CHF, cardiac arrhythmias (related to bradycardia), dilated cardiomyopathy, azotemia, renal failure or liver dysfunction
  • Cancer of the GI tract; esophagus, stomach or intestines
  • Use of appetite stimulants

Therapy:

  • Initial visit-Blood work, abdominal ultrasound, 24 hour holter monitor.
  • Subsequent visit: Blood pressure, followed by subcutaneous administration of MC4 peptide receptor antagonist, 24 hr PK sampling post drug administration.
  • Daily subcutaneous administration of MC4 peptide receptor antagonist by owner.
  • CBC, chemistry panel, UA week 2 and week 4
  • Holter monitor at week 4
  • Blood pressure checked pretreatment and at week 4.
  • Owner to complete daily diary

Benefit: Owner to pay initial office visit and bloodwork. Study covers abdominal ultrasound, cost of monitoring and treatment.     

Contact Faculty Person: Dr. Sandra Bechtel


Biodistribution of Boron Liposomes in Spontaneous Canine Cancers

The aim of this project is to determine the boron concentration of spontaneous canine tumors after administration of novel boron-containing agents. These boron concentrations will guide future boron neutron capture therapy studies used to treat canine tumors, with the goal of ultimately developing trials in human head and neck cancer. In this study, the boron compounds, which have shown to be safe in normal dogs, will be administered and the patients will receive serial biopsies to evaluate boron concentration. These dogs will not receive neutron irradiation, and thus will not receive boron neutron capture therapy.

Criteria:

  • Any histologic confirmed salivary or oral tumor or any solid tumor at least 2 cm but no greater than 5 cm
  • CBC, Chemistry panel, UA, FNA of draining lymph node, thoracic radiographs, +/- abdominal U/S
  • Adequate renal, hepatic and hematologic parameters.
  • No significant co-morbidities
  • NSAIDS or steroids are permitted if started at least 2 weeks prior to treatment
  • 10-35 kg body weight

Exclusion:

  • Osteosarcoma or round cell tumors
  • Prior chemotherapy or radiation therapy
  • Tumor < 2 cm or > 5 cm
  • History of pancreatitis or prior administration of liposomal compounds
  • Distant metastasis

Therapy:

  • Must start on Monday
  • Premedication with maropitant and diphenhydramine, administration of MAC/TAC liposome compound daily for one or two days.
  • Blood draw and biopsies at 24, and 48 hours post infusion
  • 72 hours post infusion blood draw with-incisional biopsy or tumor removal at VHC.
  • Recheck exam-10-14 days- CBC, chemistry panel, UA, boron PK, suture removal

Benefit:

  • Owner to pay initial office call and staging. Study to cover costs associated with liposome infusion, biopsies, and four days hospitalization, plus up to $1500.00 towards surgery or RT.  

      Contact Faculty Person: Dr. Charles Maitz


COTC021-OSA-SOC + Rapamycin

COTC021-OSA-SOC + Rapamycin seeks to evaluate the safety and effectiveness of Standard of Care therapy, with adjuvant rapamycin administration. Standard of Care is defined as amputation of the affected limb, followed by four doses of carboplatin given every three weeks. Dogs will be randomized to either COTC021 or COTC022 at the start of therapy, which will determine the treatment prescribed.

Criteria:

  • Appendicular osteosarcoma confirmed by histopathology or cytology
  • Normal CBC, chemistry panel, UA, abdominal ultrasound, and thoracic radiographs within 10 days of amputation at MU-VHC.
  • Patient must weigh over 25 kgs
  • No prior chemotherapy, radiation therapy or bisphosphonates
  • NSAIDS, gabapentin, tramadol allowed prior to and during study
  • Favorable performance status

Therapy:

  • Surgical amputation of affected limb at MU-VHC
  • First carboplatin infusion within 2 weeks of surgery, then every 3 weeks for total of 4 doses
  • Oral rapamycin to start within 7 days of week 15 visit- Monday –Thursday administration
  • Return visits on Days 11, and 25, then monthly of every rapamycin cycle for overnight pharmacokinetics.

Benefit:

  • Owner to pay initial office call, staging and post chemo CBC’s.
  • Owner to receive $1000.00 credit towards amputation at the MU-VHC.
  • Once enrolled study is mostly funded. Study covers following costs: drug and drug administration, blood work at chemo visits, imaging (radiographs) and VHC office calls.

Contact Faculty Person: Dr. Brian Flesner


COTC022-OSA-SOC

COTC022-OSA-SOC seeks to evaluate the safety and effectiveness of Standard of Care therapy, with adjuvant rapamycin administration. Standard of Care is defined as amputation of the affected limb, followed by four doses of carboplatin given every three weeks. Dogs will be randomized to either COTC021 or COTC022 at the start of therapy, which will determine the treatment prescribed.

Criteria:

  • Appendicular osteosarcoma confirmed by histopathology or cytology
  • Normal CBC, chemistry panel, UA, abdominal ultrasound, and thoracic radiographs within 10 days of amputation.
  • Patient must weigh over 25 kgs
  • No prior chemotherapy, radiation therapy or bisphosphonates
  • NSAIDS, gabapentin, tramadol ok prior to and during study
  • Favorable performance status

Therapy:

  • Surgical amputation of affected limb at MU-VHC
  • First carboplatin infusion within 2 weeks of surgery, then every 3 weeks for total of 4 doses

Benefit:

  • Owner to pay initial office call, staging and post chemo CBC’s.
  • Owner to receive $1000.00 credit towards amputation at the MU-VHC.
  • Once enrolled study is mostly funded. Study covers following costs: drug and drug administration, blood work at chemo visits, imaging (radiographs) and VHC office calls.

Contact Faculty Person: Dr. Brian Flesner

Laser Immunotherapy for the Treatment of Non-Resectable Canine Oral Melanoma

The primary purpose of this study is to evaluate the safety and characterize the side effects of inCVAX (autologous cancer vaccine) in treating canine oral melanoma. Dogs with naturally-occurring non-resectable (due to size, location, or owner preference) oral melanomas will be enrolled. The long term goal of this research is to establish a simplified, cost effective, tolerable and personalized immunotherapy in canine cancer.

Criteria:

  • Histologic or cytologic confirmed oral melanoma, at least 2 cm in diameter
  • CBC, Chemistry panel, UA, FNA of draining lymph node, thoracic radiographs
  • Adequate renal, hepatic and hematologic parameters.
  • No prior chemotherapy, radiation therapy, hormones, antibody, gene therapy, cancer vaccine, or immunotherapy.
  • No glucocorticoids within 4 weeks prior to study initiation
  • No significant co-morbidities
  • Expected survival > 16 weeks
  • Performance score of 0 or 1

Exclusion:

  • History of untreated or symptomatic CNS disease, including seizures
  • Tumor < 2 cm – must have tumor present at time of enrollment
  • Antibiotic use within 21 days of study enrollment

Therapy:

  • CT scan (pretreatment, week 12) and biopsy (pretreatment, week 8) of tumor at MU VHC
  • InCVAX (laser assisted immunotherapy) and GC (immune stimulant) injection once monthly for three months.
  • Immune blood collection prior to each treatment
  • Complete blood count (CBC) prior to each treatment

Benefit:

  • Initial staging costs are owner’s financial responsibility.
  • Patient to receive treatments, office calls, scheduled CT scans, radiographs and blood work at no charge.

       Contact Faculty Person: Dr. Sandra Bechtel

Golden Retrievers with New Diagnosis of Lymphoma Needed for Biopsy Study

Veterinarians at the University of Missouri, Colorado State University and Texas A&M University seek Golden Retrievers with a new diagnosis of lymphoma for an important study of lymphoma. Golden Retrievers with lymphoma that have not been treated with chemotherapy or prednisone who do not have elevated blood calcium may receive a diagnostic biopsy and flow cytometry analysis of their tumor at no cost for the procedure. Dogs must be evaluated at one of the participating Universities. This study seeks to classify B cell lymphomas more thoroughly for important clinical decision-making. It also seeks the underlying alterations in the tumor cells to provide clues for cause and for new therapy approaches. To schedule an appointment at the University of Missouri, please call (573) 882-7821. Standard consultation fees apply, but eligible dogs will receive biopsy and flow cytometry at no cost to the client. This trial is funded by the Canine Health Foundation and Morris Animal Foundation.